In the proposed rule, CMS would increase price transparency efforts by widening the scope of standard charges to include payer-specific negotiated rates and gross charges. Vizient said mandating such disclosures would hurt patient care because of “potentially misleading cost information.”
The company also criticized CMS’ proposal to continue reducing payments to hospitals that purchase 340B drugs. The company said courts determined the reductions to be unlawful.
More articles on surgery centers:
Looser ASC requirements, 24-hour stays & more: 3 regulation updates to know
Becoming an administrator & what separates ASCs from one another — 2 insights from a recruiter
Hospital-owned ASC doesn’t get tax exemption, Pennsylvania court says
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.